on The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group, Inc. Discloses Position in Avadel Pharmaceuticals
The Vanguard Group, Inc. has submitted a Form 8.3 concerning its interests in Avadel Pharmaceuticals PLC. As of January 9, 2026, Vanguard held 6.03% in ordinary shares, totaling 5,871,186 shares. The disclosure aligns with Rule 8.3 of the Irish Takeover Panel Act of 1997.
The document highlights Vanguard's recent transactions involving US$0.01 ordinary shares of Avadel Pharmaceuticals. The group purchased 1,923 shares and sold 92 shares, both at a price of 21.50 USD per share.
No cash-settled or stock-settled derivative positions were reported. Additionally, there are no relevant indemnity, option, or voting rights agreements related to Avadel shares.
The form emphasizes transparency in compliance with takeover rules while maintaining neutrality in its investments.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all The Vanguard Group, Inc. news